

## Aurélie Bardet

### Statistician

#### Professional experience

- April 2018 to date: **Statistician in Gustave Roussy cancer centre** and in Center for research in epidemiology and population health (CESP INSERM 1018, Team ONCOSTAT on methods, meta-analyses and biomarkers), Villejuif, France
- December 2014 to March 2018: **Statistician in Roche French Affiliates**, Boulogne-Billancourt, France.
  - Referent methodologist for haematology, onco-dermatology and hemophilia
- May 2012 to November 2014: **Biostatistician pharmacoepidemiologist, Institut de Recherches Internationales Servier**, Courbevoie, France.
  - Responsible for the statistical methodology of all observational studies in the company: protocol review and methodological expertise
- September 2008 to April 2012: **Acceptability data analysis officer, Institut de Recherches Internationales Servier**, Courbevoie, France.
  - Responsible for safety analyses in the field of pharmaco-epidemiology on CPRD UK database

#### Thematics of interest

Observational studies: design, propensity scores  
Causal inference  
Clustering and trajectories

#### Teaching

2018-2021: Master 2 course on censored data (6 hours), Master of Public health research, Université Paris-Saclay

2019-2020: Critical review of scientific articles, Institut de Formation Supérieure BioMédicale and Diplôme Universitaire Européen de Recherche Translationnelle Et Clinique en Cancérologie

Teaching lessons for clinicians on methodological issues and statistics fundamentals

#### Education

- 2006-2008 : ENSAE (French top school for statistics and economic administration) – national diploma of statistician economist - specialisation in biostatistics
- 2004-2008 (double diploma) : Master's degree in Econometrics, and, in Theoretical and empirical economics (Paris School of Economics) – specialisation in Econometrics, Paris I Panthéon-Sorbonne University

## Publications

H-factor : 5

### Articles :

- Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2022 Jan;23(1):104-114.
- Charles C, Bardet A, Ibrahim N, Aromatario O, Cambon L, Imbert A, Pons M, Raynard B, Sauveplane D, Pouchepadass C, Baudinet C, Lambotte O, Marabelle A, Dauchy S. Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIME-FEAS feasibility study. *J Telemed Telecare*. 2021 Jun 17:1357633X211021743.
- Bardet A, Frasin AM, Marghadi J, Borget I, Faron M, Honoré C, Delaloge S, Albiges L, Planchard D, Ducreux M, Hadoux J, Colomba E, Robert C, Bouhir S, Massard C, Micol JB, Ter-Minassian L, Michiels S, Auperin A, Barlesi F, Bonastre J. Impact of COVID-19 on healthcare organisation and cancer outcomes. *Eur J Cancer*. 2021 Aug;153:123-132.
- Borget I, Lassau N, Balleyguier C, Bardet A, Barlesi F. Imaging: towards a global solution to overcome the cancer pandemic. *Lancet Oncol*. 2021 Apr;22(4):430-432.
- Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delaloge S, Michiels S, André F, Vaz-Luis I. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. *J Clin Oncol*. 2020 Aug 20;38(24):2762-2772.
- Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Quality-of-life assessment in French patients with metastatic melanoma in real life. *Cancer*. 2020 Feb 1;126(3):611-618.
- Rossoni C, Bardet A, Georger B, Paoletti X. Sequential or combined designs for Phase I/II clinical trials? A simulation study. *Clin Trials*. 2019 Dec;16(6):635-644.
- Solal-Céligny P, Leconte P, Bardet A, Hernandez J, Troussard X. A retrospective study on the management of patients with rituximab refractory follicular lymphoma. *Br J Haematol*. 2018 Jan;180(2):217-223.
- Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O, Arkam Y, Orfeuvre H, Dilhuydy MS, Barry M, Jourdan E, Dreyfus B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M, Delmer A. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. *Leuk Lymphoma*. 2017 Jun;58(6):1366-1375.

Oral communications:

- Bardet A, Fraslin AM, Faron M, Borget I, Ter-Minassian L, Marghadi J, Aupérin A, Michiels S, Barlesi F, Bonastre J. A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden. ESMO congress Sept 2020 ; Annals of Oncology (2020) 31 (suppl\_4).

Methodological Posters :

- Generating consistent and reliable evidence on survival estimates for Health Technology Assessment in Oncology and Haematology, Grouin J, Rose M, Magrez D, Tehard B, Bardet A, ISPOR 2016
- Correction methods for unmeasured confounding in non interventional studies, Grassano L, Bardet A, Magrez D, mid-year ICPE 2017 et Journée annuelle du groupe Biopharmacie et santé de la Société Française de Statistique 2017